Innate Pharma SA
PAR:IPH

Watchlist Manager
Innate Pharma SA Logo
Innate Pharma SA
PAR:IPH
Watchlist
Price: 1.916 EUR Market Closed
Market Cap: 176.6m EUR

Wall Street
Price Targets

IPH Price Targets Summary
Innate Pharma SA

Wall Street analysts forecast IPH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IPH is 5.282 EUR with a low forecast of 2.515 EUR and a high forecast of 8.82 EUR.

Lowest
Price Target
2.515 EUR
31% Upside
Average
Price Target
5.282 EUR
176% Upside
Highest
Price Target
8.82 EUR
360% Upside
Innate Pharma SA Competitors:
Price Targets
4599
StemRIM Inc
132% Upside
2480
Beijing Luzhu Biotechnology Co Ltd
34% Upside
GNS
Genus PLC
25% Upside
1952
Everest Medicines Ltd
14% Upside
LYEL
Lyell Immunopharma Inc
94% Downside
6160
Beigene Ltd
22% Upside
300601
Shenzhen Kangtai Biological Products Co Ltd
21% Upside
VLA
Valneva SE
175% Upside

Revenue
Forecast

Revenue Estimate
Innate Pharma SA

For the last 8 years the compound annual growth rate for Innate Pharma SA's revenue is -17%. The projected CAGR for the next 3 years is 79%.

-17%
Past Growth
79%
Estimated Growth
Estimates Accuracy
-24%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Innate Pharma SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
24%
Average Beat

Net Income
Forecast

Net Income Estimate
Innate Pharma SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
53%
Average Beat
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is IPH's stock price target?
Price Target
5.282 EUR

According to Wall Street analysts, the average 1-year price target for IPH is 5.282 EUR with a low forecast of 2.515 EUR and a high forecast of 8.82 EUR.

What is Innate Pharma SA's Revenue forecast?
Projected CAGR
79%

For the last 8 years the compound annual growth rate for Innate Pharma SA's revenue is -17%. The projected CAGR for the next 3 years is 79%.

Back to Top